The effects of L-carnitine supplementation on inflammation, oxidative stress, and clinical outcomes in critically Ill patients with sepsis: a randomized, double-blind, controlled trial

Sepsis, a life-threatening organ dysfunction caused by a host's dysregulated response to infection with an inflammatory process, becomes a real challenge for the healthcare systems. L-carnitine (LC) has antioxidant and anti-inflammatory properties as in previous studies. Thus, we aimed to deter...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition journal 2024-03, Vol.23 (1), p.31-31, Article 31
Main Authors: Keshani, Mahdi, Alikiaii, Babak, Babaei, Zahra, Askari, Gholamreza, Heidari, Zahra, Sharma, Manoj, Bagherniya, Mohammad
Format: Article
Language:English
Subjects:
Albumin
Anti-inflammatory agents
Antioxidants
Antioxidants - therapeutic use
Biomarkers
C-Reactive Protein
Carnitine
Carnitine - therapeutic use
Clinical outcomes
Clinical trial
Clinical trials
Critical Illness
Critically ill
Cytokines
Diagnosis
Dietary Supplements
Disease
Dosage and administration
Drug therapy
Erythrocyte sedimentation rate
Gram-positive bacteria
Hospitals
Humans
Hypoxia
Immune system
Infection
Infections
Inflammation
Inflammation - drug therapy
Informed consent
Intervention
L-carnitine
Levocarnitine
Medical research
Medicine, Experimental
Mortality
Oxidative Stress
Pathogens
Patient outcomes
Patients
Placebos
Sepsis
Sepsis - drug therapy
Statistical analysis
Superoxide
Superoxide Dismutase
Testing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sepsis, a life-threatening organ dysfunction caused by a host's dysregulated response to infection with an inflammatory process, becomes a real challenge for the healthcare systems. L-carnitine (LC) has antioxidant and anti-inflammatory properties as in previous studies. Thus, we aimed to determine the effects of LC on inflammation, oxidative stress, and clinical parameters in critically ill septic patients. A randomized double-blinded controlled trial was conducted. A total of 60 patients were randomized to receive LC (3 g/day, n = 30) or placebo (n = 30) for 7 days. Inflammatory and oxidative stress parameters (C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), superoxide dismutase (SOD), malondialdehyde (MDA), total antioxidant capacity (TAC), 28-day mortality rate, and some monitoring variables were evaluated. There was no statistically significant difference between study arms in baseline characteristics and disease severity scores. CRP (p 
ISSN:1475-2891
1475-2891
DOI:10.1186/s12937-024-00934-4